Psoriasis
From the Journals
Low-dose methotrexate carries higher risk for older patients with CKD
Adverse event data showed an increased risk of myelosuppression, sepsis, pneumotoxic effects, or hepatotoxic effects.
Latest News
Nail psoriasis in Black patients often overlooked
Clinical training might explain the delay in diagnosis of nail psoriasis in patients with darker skin types.
Latest News
Parent concerns a factor when treating eczema in children with darker skin types
For the parent, the pigmentation changes, rather than the inflammation, might be the governing issue and the reason that he or she brought the...
Case Letter
Paradoxical Reaction to TNF-α Inhibitor Therapy in a Patient With Hidradenitis Suppurativa
Clinicians need to be aware of the potential risk for a paradoxical reaction in patients receiving a tumor necrosis factor α (TNF-α) inhibitor for...
Conference Coverage
TNF blockers not associated with poorer pregnancy outcomes
Patients with rheumatic disease who continued TNF blockers during their pregnancy did not have an increased risk of worse fetal and maternal...
Latest News
The challenges of palmoplantar pustulosis and other acral psoriatic disease
Dermatologists are using a variety of treatments for palmoplantar pustulosis, with no clear first-line choices.
Latest News
Review estimates acne risk with JAK inhibitor therapy
Acne has been reported to be an adverse effect of JAK inhibitors, but not much is known about how common acne is overall.
Conference Coverage
Researchers tease apart multiple biologic failure in psoriasis, PsA
Patients failing two or more biologic agents of different mechanistic classes “are really suffering. We need to have better guidelines and...
Latest News
Most patients with psoriasis not engaged in highly shared decision-making
“It is important to construct a framework for carrying out SDM with patients with psoriasis to enhance clinician-patient communication and improve...
News from the FDA/CDC
FDA OKs first ustekinumab biosimilar
The drug has also been granted an interchangeability designation and has been approved for six indications.
Latest News
Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications
Of the 35 trials studied, most involved patients with atopic dermatitis.